Stock Movers Palantir Rises, Caterpillar Falls, Hims & Hers Drops on Earnings, Vertex Plunges on Drug Results
4 snips
Aug 5, 2025 Palantir's shares soar following a stunning 48% revenue boost, driven by AI's impact. Meanwhile, Caterpillar faces a troubling decline after missing earnings expectations, attributing losses to rising tariffs. Hims & Hers sees a drop in its stock due to revenue shortfalls. Additionally, Vertex's shares take a hit as its experimental pain drug fails to demonstrate efficacy post-surgery. The discussion also touches on investment strategies and the importance of aligning investments with personal goals.
AI Snips
Chapters
Transcript
Episode notes
Palantir's Strong AI-Driven Growth
- Palantir's revenue grew 48% driven by strong government and commercial contract growth.
- AI demand robust; commercial revenue surged 93% in a key growth indicator.
Caterpillar Profit Hit by Tariffs
- Caterpillar missed EPS estimates due to tariff impacts biting into profitability.
- Projected tariff costs drag margins 200-300 basis points despite expected sales growth.
Hims & Hers Revenue Misses Due to FDA Crackdown
- Hims & Hers stock drops on Q2 revenue miss driven by weight loss drug sales.
- FDA halted sales of copycat weight loss drugs fueling prior stock rise.